Skip to main content

Advertisement

SpringerLink
Log in

Die LAP07-Studienergebnisse sollten nicht als Aus der Radiochemotherapie für das Pankreaskarzinom missverstanden werden

The results of the LAP07 trial should not be misunderstood as the end of chemoradiotherapy in pancreatic cancer

  • Literatur kommentiert
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM et al (2009) DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 27(11):1806–1813. doi:10.1200/jco.2008.17.7188

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P et al (2016) Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA 315(17):1844–1853. doi:10.1001/jama.2016.4324

    Article  CAS  PubMed  Google Scholar 

  3. Wang JP, Wu CY, Yeh YC, Shyr YM, Wu YY, Kuo CY et al (2015) Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial. Oncotarget 6(20):18162–18173

    Article  PubMed  PubMed Central  Google Scholar 

  4. Huguet F, Andre T, Hammel P, Artru P, Balosso J, Selle F et al (2007) Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 25(3):326–331

    Article  CAS  PubMed  Google Scholar 

  5. Mahadevan A, Miksad R, Goldstein M, Sullivan R, Bullock A, Buchbinder E et al (2011) Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer. Int J Radiat Oncol Biol Phys 81(4):e615–22

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Strahlenheilkunde, Universitätsklinikum Freiburg, Albert-Ludwigs-Universität Freiburg, Robert‑Koch‑Str. 3, 79106, Freiburg, Deutschland

    Thomas Brunner

  2. Frankfurt/Main, Deutschland

    Emmanouil Fokas

Authors
  1. Thomas Brunner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emmanouil Fokas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Brunner.

Ethics declarations

Interessenkonflikt

T. Brunner und E. Fokas geben an, dass kein Interessenkonflikt besteht.

Additional information

Originalpublikation Hammel P, Huguet F, van Laethem JL et al (2016) Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA 315(17):1844–1853

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Brunner, T., Fokas, E. Die LAP07-Studienergebnisse sollten nicht als Aus der Radiochemotherapie für das Pankreaskarzinom missverstanden werden. Strahlenther Onkol 192, 956–958 (2016). https://doi.org/10.1007/s00066-016-1058-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00066-016-1058-9

Search

Navigation